Advanced search
Publication Cover
Future Science OA Volume 10, 2024 - Issue 1
Submit an article Journal homepage
316
Views
0
CrossRef citations to date
0
Altmetric
Case Report

Surgical resection due to poor outcome of the immunotherapy of a relapsed mediastinal liposarcoma: a case report

Ming-Ji Wang1 Department of Thoracic Surgery, Fuqing City Hospital Affiliated to Fujian Medical University, Fuqing, PR ChinaCorrespondence[email protected]
View further author information
,
Shu-Quan Xu2 School of Medicine, Tongji University, Shanghai, PR ChinaView further author information
,
Lei-Lei Wu3 Department of Thoracic Surgery, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai, PR ChinaORCID Iconhttps://orcid.org/0000-0002-7417-6864View further author information
ORCID Icon,
Zhi-Xin Li3 Department of Thoracic Surgery, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai, PR ChinaView further author information
&
Dong Xie3 Department of Thoracic Surgery, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai, PR ChinaCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0002-3715-1801View further author information
ORCID Icon
Article: FSO906 | Received 06 Jun 2023, Accepted 18 Sep 2023, Published online: 30 Oct 2023

References

  • Suster DI, Suster S. Liposarcomas of the mediastinum. Mediastinum 30(4), 27 (2020).
  • Gronchi A, Strauss DC, Miceli R et al. Variability in patterns of recurrence after resection of primary retroperitoneal sarcoma (RPS): a report on 1007 patients from the multi-institutional collaborative RPS working group. Ann. Surg. 263(5), 1002–1009 (2016).
  • Mulita F, Verras GI, Liolis E et al. Recurrent retroperitoneal liposarcoma: a case report and literature review. Clin. Case. Rep. 30, 9(9), e04717 (2021).
  • Haddox CL, Riedel RF. Recent advances in the understanding and management of liposarcoma. Fac. Rev. 4(10), 1 (2021).
  • Yu WD, Sun G, Li J, Xu J, Wang X. Mechanisms and therapeutic potentials of cancer immunotherapy in combination with radiotherapy and/or chemotherapy. Cancer Lett. 452(28), 66–70 (2019).
  • Rugge M, Buja A, Tropea S et al. Indicators of clinical performance in monitoring soft tissue sarcoma management: a population-based perspective. Front. Med (Lausanne). 8(10), 1226090 (2023).
  • Tawbi HA, Burgess M, Bolejack V et al. Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase II trial. Lancet. Oncol. 18(11), 1493–1501 (2017).
  • Verras GI, Mulita F, Bouchagier K et al. Mid-term outcomes in the treatment of retroperitoneal sarcomas: a 12-year single-institution experience. Med. Glas (Zenica). 19(2), doi: 10.17392/1498-22 (2022).
  • Keung EZ, Burgess M, Salazar R et al. Correlative analyses of the SARC028 trial reveal an association between sarcoma-associated immune infiltrate and response to pembrolizumab. Clin. Cancer. Res. 26(6), 1258–1266 (2020).
  • Bock S, Hoffmann DG, Jiang Y, Chen H, Il'yasova D. Increasing incidence of liposarcoma: a population-based study of national surveillance databases, 2001–2016. Int. J. Environ. Res. Public. Health. 17(8), 2710 (2020).
  • Gadgeel S, Rodríguez-Abreu D, Speranza G et al. Updated analysis from KEYNOTE-189: pembrolizumab or placebo plus pemetrexed and platinum for previously untreated metastatic nonsquamous non-small-cell lung cancer. J. Clin. Oncol. 38(14), 1505–1517 (2020).
  • Tyler R, Wanigasooriya K, Taniere P et al. A review of retroperitoneal liposarcoma genomics. Cancer Treat. Rev. 86, 102013 (2020).
  • Dickson MA, Tap WD, Keohan ML et al. Phase II trial of the CDK4 inhibitor PD0332991 in patients with advanced CDK4-amplified well-differentiated or dedifferentiated liposarcoma. J. Clin. Oncol. 31(16), 2024–2028 (2013).
  • Pandey K, An HJ, Kim SK et al. Molecular mechanisms of resistance to CDK4/6 inhibitors in breast cancer: a review. Int. J. Cancer 145(5), 1179–1188 (2019).
  • Deng H, Zhao Y, Cai X et al. PD-L1 expression and tumor mutation burden as Pathological response biomarkers of neoadjuvant immunotherapy for early-stage non-small cell lung cancer: a systematic review and meta-analysis. Crit. Rev. Oncol. Hematol. 170, 103582 (2022).
  • Usmanij EA, de Geus-Oei LF, Troost EG et al. 18F-FDG PET early response evaluation of locally advanced non-small cell lung cancer treated with concomitant chemoradiotherapy. J. Nucl. Med. 54(9), 1528–1534 (2013).
  • Chen D, Zhang C, Zang Y, Wang W, Zhang J. Identification of an immune-related gene prognostic index for predicting survival and immunotherapy efficacy in papillary renal cell carcinoma. Front. Genet. 13, 970900 (2022).

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.